Unilateral Cervical Polyneuropathies following Concurrent Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer

Elghouche, Alhasan N.; Shokri, Tom; Qin, Yewen; Wargo, Susannah; Citrin, Deborah E.; Waes, Carter Van

doi:10.1155/2016/2313714

Cited by 5 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another case published in the literature, unilateral cervical polyneuropathies, including phrenic nerve palsy, developed in a patient who was given simultaneous bortezomib, cetuximab, and radiotherapy for head and neck cancer. 10 However, the neuropathies described in this case report could not be attributed to acute bortezomib toxicity; because bortezomib-related neuropathies typically occur during treatment and are reversible. 2,11 Sequelae neuropathies in the patient presented in this case showed that bortezomib neurotoxicity potentiates or is potentiated by concomitant radiotherapy and/or EGFR inhibition effect.…”

Section: Discussionmentioning

confidence: 66%

Asymptomatic unilateral phrenic nerve palsy after bortezomib treatment in a newly diagnosed multiple myeloma patient

Coşkunpınar

Erdoğdu

Göker

2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Bortezomib is the first chemotherapeutic agent of proteosome inhibitor class that can be used in newly diagnosed and relapsed/refractory multiple myeloma. It is well known that bortezomib has side effects such as peripheral sensory, motor, or autonomic neuropathy. In this paper, we will present our patient who developed unilateral phrenic nerve palsy as an autonomic neuropathy after six cycles of subcutaneous bortezomib treatment. This case differs from other cases in that our patient was asymptomatic. Case report A 57-year-old male patient was admitted with back pain and gait disturbances. In the thorax computed tomography, a soft tissue mass causing compression on the spinal canal was observed in the T12 vertebra. Bone biopsy pathology report resulted in diffuse plasma cell infiltration. The patient was diagnosed with stage ISS-3, IgG kappa type multiple myeloma. Management and outcome Subcutaneous bortezomib 1 × 2.2 mg (Days 1-4-8-11) + intravenous cyclophosphamide 1000 mg (Day 1) + intravenous dexamethasone 40 mg (Days 1-2-3-4) (VCD chemotherapy protocol) was started. Totally six cycles of VCD were administered. While the patient did not have any respiratory symptoms, an elevation consistent with phrenic nerve palsy was observed in the left hemidiaphragm in the thorax computed tomography that was taken during the preparation for autologous hematopoietic stem cell transplantation. Discussion Bortezomib is a frequently used chemotherapeutic agent in patients with multiple myeloma and care should be taken in terms of the risk of developing phrenic nerve palsy in patients. There are cases of autonomic neuropathy developing after bortezomib treatment.

show abstract

Section: Discussionmentioning

confidence: 66%

Asymptomatic unilateral phrenic nerve palsy after bortezomib treatment in a newly diagnosed multiple myeloma patient

Coşkunpınar

Erdoğdu

Göker

2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…In addition, we found significant differences and correlations between high-and lowrisk patients with high sensitivity to drugs, such as Bortezomib_1191, Luminespib_1559, and Rapamycin_1084, suggesting that these three drugs may be used in the treatment of high-risk CESC patients. Previous studies found that Bortezomib was indeed effective in the treatment of CESC patients [61][62][63][64]. In combination therapy, Bortezomib significantly increases the sensitivity of multiple agents to CESC [61][62][63][64].…”

Section: Discussionmentioning

confidence: 93%

“…Previous studies found that Bortezomib was indeed effective in the treatment of CESC patients [61][62][63][64]. In combination therapy, Bortezomib significantly increases the sensitivity of multiple agents to CESC [61][62][63][64]. The mechanistic target of Rapamycin (mTOR) is an atypical serine/threonine kinase that plays an important role for several cancers, including cervical cancer [65][66][67].…”

Section: Discussionmentioning

confidence: 99%

Prediction of Prognosis and Chemotherapeutic Sensitivity Based on Cuproptosis-Associated lncRNAs in Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma

Zhou

et al. 2023

Genes

View full text Add to dashboard Cite

Cervical cancer is the fourth most common cancer. The 5-year survival rate for metastatic cervical cancer is less than 10%. The survival time of patients with recurrent cervical cancer is approximately 13–17 months. Cuproptosis is a novel type of cell death related to mitochondrial respiration. Accumulative studies showed that long non-coding RNAs (lncRNAs) regulated cervical cancer progression. Compressive bioinformatic analysis showed that nine cuproptosis-related lncRNAs (CRLs), including C002128.2, AC002563.1, AC009237.14, AC048337.1, AC145423.1, AL117336.1, AP001542.3, ATP2A1-AS1, and LINC00426, were independently correlated with the overall survival (OS) of cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) patients. The time-dependent area under curve value reached 0.716 at 1 year, 0.718 at 3 years, and 0.719 at 5 years. Notably, CESC patients in the low-risk group had increased immune cell infiltration and expression of several immune checkpoints, which indicated that they may benefit more from immune checkpoint blockade therapy. In addition, we also used the model for drug sensitivity analysis. Several drug sensitivities were more sensitive in high-risk patients and showed significant correlations with the risk models, such as Bortezomib_1191, Luminespib_1559, and Rapamycin_1084, suggesting that these drugs may be candidate clinical drugs for patients with a high risk of CESC. In summary, this study further explored the mechanism of CRLs in CESC and provided a more optimized prognostic model and some insights into chemotherapy of CESC.

show abstract

“…For head and neck tumors, bortezomib does not significantly inhibit proliferation-related pathways, such as STAT3, and has no significant effect on the expression of EGFR; therefore, it has poor efficacy in HNSCC in drug experiments and clinical applications [27,28]. Nevertheless, the role of PIs in the treatment of other tumors still provides new thinking for the treatment of head and neck tumors, and some studies are currently underway [29][30][31]. This study, for the first time, elucidated the effect of proteasome inhibition on the UPP and PSMB8 in laryngeal and hypopharyngeal carcinoma cells.…”

Section: Discussionmentioning

confidence: 99%

Induction and Regulation of the Immunoproteasome Subunit β5i (PSMB8) in Laryngeal and Hypopharyngeal Carcinoma Cells

Nan-xiang

Liu

et al. 2020

Med Sci Monit

View full text Add to dashboard Cite

Departmental sources Background: The ubiquitin-proteasome pathway (UPP) is closely associated with the occurrence and progression of cancer, and the 5i immunoproteasome subunit is an important antitumor target in UPP. This study aimed to characterize the regulation of the immunoproteasome subunit b5i (PSMB8) in JHU-011 laryngeal carcinoma cells and FaDu hypopharyngeal carcinoma cells to explore a new target for the treatment of laryngeal and hypopharyngeal carcinomas. Material/Methods: JHU-011 and FaDu cells were used as effector cells in this study. By means of 60 Co g-irradiation, the construction of stable cell lines of the silenced proto-oncogene c-Abl, and the addition of exogenous tyrosine kinase inhibitor (TKI) and activator, the transcription and protein expression levels of PSMB8 and its alternatively spliced isoforms in both cell lines were detected by real-time fluorescence quantitative polymerase chain reaction (RT-PCR) and Western blot. Results: Ionizing radiation upregulated the transcription level of the alternatively spliced isoform of PSMB8, E2, in both cell lines, thereby upregulating the mRNA and protein levels of PSMB8. The silencing of the proto-oncogene c-Abl and the activation and inhibition of its kinetic kinase product can affect the transcription and protein levels of PSMB8. Conclusions: Ionizing radiation can significantly upregulate the mRNA and protein levels of PSMB8, which happens through the upregulation of its splicing isoform E2. The proto-oncogene c-Abl and its kinetic kinase protein product can regulate the transcription and protein expression levels of PSMB8 and its alternatively spliced isoforms.

show abstract

Unilateral Cervical Polyneuropathies following Concurrent Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer

Cited by 5 publications

References 25 publications

Asymptomatic unilateral phrenic nerve palsy after bortezomib treatment in a newly diagnosed multiple myeloma patient

Asymptomatic unilateral phrenic nerve palsy after bortezomib treatment in a newly diagnosed multiple myeloma patient

Prediction of Prognosis and Chemotherapeutic Sensitivity Based on Cuproptosis-Associated lncRNAs in Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma

Induction and Regulation of the Immunoproteasome Subunit β5i (PSMB8) in Laryngeal and Hypopharyngeal Carcinoma Cells

Contact Info

Product

Resources

About